While pola-R-CHP was associated with more febrile neutropenia compared to R-CHOP (13.8% versus 8.0%, respectively), the number of patients who had grade 3/4 infections, or had to discontinue one of the drugs due to infection or neutropenia, were similar between the two treatment arms. This evidence concerns the gene POLA1 and neutropenia.